Table 1.
Basic characteristics of alendronate-treated and nontreated patients
| Alendronate treated (n=37), n (%) | Nontreated (n=33), n (%) | P# | Adjusted mean difference | L | U | Adjusted P$ | |
|---|---|---|---|---|---|---|---|
| Age (years) | 69.59±5.97 | 68.72±4.04 | 0.48 | - | - | - | - |
| BMI (kg/m2) | 27.07±3.76 | 28.08±3.50 | 0.25 | - | - | - | - |
| Follow-up (months) | 20.89±2.73 | 20.84±2.76 | 0.92 | - | - | - | - |
| Hypertension (%) | 16 (43.2) | 14 (42.4) | 0.94 | - | - | - | - |
| Diabetes mellitus (%) | 10 (27) | 10 (30.3) | 0.76 | - | - | - | - |
| CAD history (%) | 24 (64.9) | 18 (54.5) | 0.38 | - | - | - | - |
| Statin use (%) | 33 (89.2) | 32 (97) | 0.21 | - | - | - | - |
| Beta-blocker use (%) | 26 (70.3) | 19 (57.6) | 0.27 | - | - | - | - |
| ACEI/ARB use (%) | 15 (40.4) | 14 (42.4) | 0.87 | - | - | - | - |
| Hemoglobin (g/dL) | 12.87±0.70 | 12.99±0.83 | 0.52 | −0.11 | −0.48 | 0.27 | 0.577 |
| Platelet (/µL) | 201.78±49.70 | 212.36±56.29 | 0.41 | −10.87 | −34.90 | 13.17 | 0.370 |
| Creatinine (mg/dL) | 1.11±0.13 | 1.39±1.6 | 0.84 | −0.30 | −0.85 | 0.25 | 0.283 |
| FBS (mg/dL) | 106.08±23.13 | 99.51±13.78 | 0.44 | 7.58 | 0.41 | 14.74 | 0.039 |
| Triglyceride (mg/dL) | 118.75±28.66 | 113.69±25.9 | 0.43 | 6.15 | −6.76 | 19.07 | 0.345 |
| LDL-C (mg/dL) | 87.48±15.16 | 85.45±15.61 | 0.58 | 1.59 | −5.85 | 9.04 | 0.671 |
| HDL-C (mg/dL) | 47.89±7.48 | 46.72±5.74 | 0.47 | 0.62 | −2.54 | 3.78 | 0.697 |
| Uric acid (mg/dL) | 5.43±0.73 | 5.19±0.58 | 0.23 | 0.27 | −0.07 | 0.60 | 0.116 |
| ALT (IU/L) | 25.24±5.58 | 24.27±6.16 | 0.31 | 0.88 | −1.98 | 3.74 | 0.540 |
| AST (IU/L) | 23.62±5.47 | 25.93±6.28 | 0.11 | −2.14 | −5.06 | 0.79 | 0.150 |
| Calcium (mg/dL) | 9.06±0.37 | 9.06±0.36 | 0.94 | 0.00 | −0.18 | 0.18 | 0.971 |
| Albumin (g/dL) | 4.06±0.24 | 4.12±0.24 | 0.29 | −0.05 | −0.17 | 0.07 | 0.393 |
| Phosphorus (mg/dL) | 3.87±0.52 | 3.77±0.29 | 0.71 | 0.09 | −0.12 | 0.30 | 0.379 |
| PTH (pg/mL) | 54.75±10.73 | 53.12±9.50 | 0.50 | 0.22 | −4.49 | 4.92 | 0.928 |
| Serum Vitamin D level (ng/mL) | 43.58±6.57 | 44.36±10.01 | 0.69 | −1.17 | −5.33 | 2.99 | 0.577 |
| NT-pro-BNP (pg/mL) | 1258±986 | 1053±741 | 0.29 | 115.39 | −305.86 | 536.63 | 0.586 |
BMI=Body mass index; FBS=Fast blood sugar; LDL-C=Low-density lipoprotein; HDL-C=High-density lipoprotein; PTH=Parathyroid hormone; CAD=Coronary artery disease; ACEI=Angiotensin-converting enzyme inhibitor; ARB=Angiotensin receptor blocker; NT-Pro-BNP=N-terminal-prohormone of brain natriuretic peptide. Data are expressed as mean±SD and frequency (%) for numeric and categorical variables, respectively. #Based on t/Chi-square test for numeric/categorical variables. $Adjusted for age, BMI, and follow-up time; L=95% CI lower bound; U: 95% CI upper bound. CI=Confidence interval; SD=Standard deviation; ALT=Alanine aminotransferase; AST=Aspartate aminotransferase